The FTC has cleared Gilead Sciences’s $11 billion acquisition of a rival firm, Pharmasset, after Gilead withdrew and refiled its Hart-Scott-Rodino forms in late December. Gilead said it submitted the forms...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: